Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: J Allergy Clin Immunol. 2012 Nov 30;131(1):10.1016/j.jaci.2012.10.026. doi: 10.1016/j.jaci.2012.10.026

FIG 1.

FIG 1

Oral sensitization and anaphylaxis in Il4raF709 mice: prevention of oral sensitization by antigen-specific Treg cells. A, Il4raF709 and WT BALB/c control mice were either sham sensitized with PBS or sensitized with OVA (100 μg) or OVA/SEB (100 μg/10 μg) by means of gastric gavage once weekly for 8 weeks. Select groups of mice were administered intravenously at the start of the sensitization protocol (day 0), either 5 × 105 cells of DO11.10+ Treg(TR) cells isolated from DO11.10+Foxp3EGFP mice or PBS. At the end of the sensitization period, mice were challenged with 5 mg of OVA by means of gastric gavage and monitored for rectal temperature changes. B, Total (left) and OVA-specific (right) serum IgE levels measured after OVA challenge. C, Enumeration of mast cell infiltration of small intestinal tissues of sensitized mice. D, Serum mMCP-1 levels in mice after OVA challenge. E, Small intestinal histopathology of sham (PBS)–sensitized, OVA-sensitized, and OVA-sensitized/DO11.10+ Treg cell–treated mice (toluidine blue staining; original magnification ×200). Results represent data on 5 to 10 mice per group derived from 2 independent experiments. *P < .05 and ***P < .001,2-way ANOVA.